ClinicalTrials.gg
CompletedNCT02008396Updated Jun 5, 2025Results posted

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

A Phase 2 interventional study of Placebo and Midomafetamine HCl in Social Anxiety in Autistic Adults, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Enrollment
430th of 504
12 · median 44
Started
2014
with 26 others
Phase 2
95 of 603
11 open now
Registered
246th of 603
by date

Among the 603 studies in Autistic Disorder with a site in United States, this one is the 430th largest by enrollment of the 504 interventional ones that give a count, is one of 27 that started in 2014, is one of 95 in phase 2, and was the 246th registered.

Autistic Disorder

1,034 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing social anxiety in adults with autism.

The main questions it aims to answer are:

  • Do two sessions of MDMA-assisted therapy reduce social anxiety?
  • What dose of MDMA is most effective at reducing social anxiety?

Researchers will compare two blinded sessions of MDMA-assisted therapy to two blinded sessions of placebo with therapy.

Participants will undergo three non-drug preparatory therapy sessions before the first blinded medication session. After each medication session, participants will undergo three non-drug integrative therapy sessions.

In Stage 2, participants who received placebo with therapy in the first two blinded sessions will be able to undergo two sessions with MDMA-assisted therapy.

Read the detailed description

The main objective of this study was to collect safety data to examine whether MDMA-assisted therapy was tolerated and to estimate symptom reduction in social anxiety and other psychiatric symptoms that are common in the adult autistic population as evaluated by standard clinical measures. The primary outcome measure was change in social anxiety symptoms as measured by the Liebowitz Social Anxiety Scale (LSAS) [Heimberg et al., 1999].

Each of the 12 subjects participated in two blinded experimental sessions, with either MDMA or placebo, which lasted seven hours. Before experimental sessions, participants underwent three separate hour-long preparatory sessions to learn what to expect and complete pre-treatment assignments. After each experimental session, participants underwent three separate hour-long integrative sessions to help integrate their experiences and insights from the experimental sessions.

This study was designed as a dose escalation study to assist with the exploration of safety and finding the most effective dose in this population. Upon enrollment, participants (Group 1) were randomized to receive one dose of either placebo or 75 mg of midomafetamine HCl. In the second experimental session one month later, Group 1 subjects randomized to MDMA escalated to 100 mg of midomafetamine HCl, unless contraindicated. The second group of subjects enrolled (Group 2) were randomized to receive one dose of either placebo or 100 mg of midomafetamine HCl. In the second experimental session one month later, Group 2 subjects randomized to MDMA escalated to 125 mg of midomafetamine HCl, unless contraindicated.

The blind was maintained through the six-month follow-up. In Stage 2 after the blind was broken, subjects who received placebo in Stage 1 were offered an open-label extension with two experimental sessions of MDMA-assisted therapy scheduled one month apart. Subjects received 75 mg of midomafetamine HCl in the first session and escalated to 125 mg of midomafetamine HCl in the second session, unless contraindicated.

03

Conditions studied

  • Social Anxiety in Autistic Adults

Browse trials for

Keywords

  • MDMA
  • autism
  • social anxiety
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of Autism Spectrum Disorder.
  • Have social anxiety.
  • Are at least 21 years old.
  • Have completed two years of college-level education or comparable vocational training.
  • Are willing to refrain from psychiatric medication for at least 5 half-lives plus a week prior to experimental session.
  • Agree to follow all study-related instructions and restrictions, including restrictions on food, alcohol and caffeine consumption prior to experimental sessions.
  • Are willing to commit to preparatory sessions, medication management, experimental sessions, follow-up sessions and to complete evaluation instruments.
  • Agree not to use MDMA/ecstasy outside of study sessions during the study, including the follow up period.
  • Are willing to be contacted on a daily basis for a week after each experimental session.
  • Are willing to provide a contact that is willing and able to be reached by investigators, accompany the subject during some or all of the study visits, and complete study measures.
  • Are willing to give blood samples.
  • Are proficient in speaking and reading English. Subjects communicating with text-to-speech technology will also be permitted to enroll.

Exclusion criteria

Exclusion Criteria:

  • Upon review of medical or psychiatric history must not have any current or past diagnosis that would be considered a risk to participation in the study.
  • Are abusing illegal drugs.
  • Are not able to give adequate .
  • Are not able to attend face-to-face visits or those who plan to move out of the area within the treatment period.
  • Are pregnant or nursing, or if are able to bear children and do not practice an effective means of .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Placebo comparator
    Inactive Placebo with Therapy

    Participants will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.

    Drug: Placebo · Behavioral: Therapy

  • Experimental
    Group 1: MDMA-assisted therapy 75 mg/100mg

    Participants will receive 75 mg and 100 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.

    Drug: Midomafetamine HCl · Behavioral: Therapy

  • Experimental
    Group 2: MDMA-assisted therapy 100 mg/125 mg

    Participants will receive 100 mg and 125 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.

    Drug: Midomafetamine HCl · Behavioral: Therapy

Interventions

  • DrugPlacebo

    Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.

    Also known as: Inactive placebo

  • Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.

    Also known as: 3,4-methylenedioxymethamphetamine, MDMA

  • BehavioralTherapy

    Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.

    Also known as: Manualized therapy

06

What researchers measure

Primary outcomes

  1. Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2

    The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms.

    Time frame: 1-Month Post Experimental Session 2

  2. Change in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2

    The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms.

    Time frame: Baseline to 1-Month Post Experimental Session 2

07

Results

Posted Oct 14, 2020

Participant flow

Subjects were recruited by printed or internet advertisements, referrals from other health-care practitioners, and word-of-mouth. Potential participants were people, aged 21 or older, with a confirmed diagnosis of autism. The study was conducted at Los Angeles Biomedical Research Institute in Torrance, CA between February 2014 and October 2017.

Stage 1
Participant flow — Stage 1
MilestoneInactive Placebo With PsychotherapyGroup 1: MDMA-assisted Therapy 75mg/100mgGroup 2: MDMA-assisted Therapy 100mg/125mg
Started444
Completed344
Not completed100
Stage 2
Participant flow — Stage 2
MilestoneInactive Placebo With PsychotherapyGroup 1: MDMA-assisted Therapy 75mg/100mgGroup 2: MDMA-assisted Therapy 100mg/125mg
Started300
Completed300
Not completed000

Outcome measures

PrimaryLiebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2

The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms.

Time frame:
1-Month Post Experimental Session 2
Reported as:
Mean · score on a scale
Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2
score on a scaleGroup 1: MDMA-assisted Therapy 75mg/100mgGroup 2: MDMA-assisted Therapy 100mg/125 mgInactive Placebo With Psychotherapy
Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 234.3 ± 10.4155.5 ± 11.4764.0 ± 13.34
PrimaryChange in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2

The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms.

Time frame:
Baseline to 1-Month Post Experimental Session 2
Reported as:
Mean · score on a scale
Change in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2
score on a scaleGroup 1: MDMA-assisted Therapy 75mg/100mgGroup 2: MDMA-assisted Therapy 100mg/125mgInactive Placebo With Psychotherapy
Change in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2-51.0 ± 8.19-39.0 ± 17.57-19.3 ± 18.77

Adverse events

Collected over All AEs from baseline to the end of stage 2 (approximately 10 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: MDMA-assisted Therapy 75mg/100mg0/4 (0%)0/4 (0%)1/4 (25%)
Group 2: MDMA-assisted Therapy 100mg/125mg0/4 (0%)0/4 (0%)4/4 (100%)
Inactive Placebo With Psychotherapy (Stage 1)0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventGroup 1: MDMA-assisted Therapy 75mg/100mgGroup 2: MDMA-assisted Therapy 100mg/125mgInactive Placebo With Psychotherapy (Stage 1)
Depressed moodPsychiatric disorders0/42/40/4
AnxietyPsychiatric disorders0/41/40/4
Irritable bowel syndromeGastrointestinal disorders0/40/41/4
SinusitisInfections and infestations0/40/41/4
Upper respiratory tract infectionInfections and infestations0/41/41/4
DepressionPsychiatric disorders1/40/41/4
Suicidal ideationPsychiatric disorders1/41/41/4
PainGeneral disorders0/41/40/4
PyrexiaGeneral disorders0/41/40/4
NasopharyngitisInfections and infestations0/41/40/4

Baseline characteristics

Safety Set

Age, Continuous
Age, Continuous(years)Inactive Placebo With PsychotherapyGroup 1 MDMA-assisted Therapy 75mg/100mgGroup 2 MDMA-assisted Therapy 100mg/125mgTotal
Mean28.27 ± 3.7737.93 ± 12.2527.77 ± 5.8731.32 ± 8.83
Sex: Female, Male
Sex: Female, Male(Participants)Inactive Placebo With PsychotherapyGroup 1 MDMA-assisted Therapy 75mg/100mgGroup 2 MDMA-assisted Therapy 100mg/125mgTotal
Female0112
Male43310
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inactive Placebo With PsychotherapyGroup 1 MDMA-assisted Therapy 75mg/100mgGroup 2 MDMA-assisted Therapy 100mg/125mgTotal
Hispanic or Latino0033
Not Hispanic or Latino4419
Unknown or Not Reported0000
Baseline Liebowitz Social Anxiety Scale (LSAS) Score
Baseline Liebowitz Social Anxiety Scale (LSAS) Score(units on a scale)Inactive Placebo With PsychotherapyGroup 1 MDMA-assisted Therapy 75mg/100mgGroup 2 MDMA-assisted Therapy 100mg/125mgTotal
Mean83.3 ± 11.8789.0 ± 8.6094.5 ± 22.1388.9 ± 14.67
08

Study locations

1 site
  • Los Angeles Biomedical Research Institute
    Torrance, California 90502, United States
09

References and documents

Publications

  • Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med. 1999 Jan;29(1):199-212. doi: 10.1017/s0033291798007879. PubMed 10077308 ↗
  • Danforth AL, Grob CS, Struble C, Feduccia AA, Walker N, Jerome L, Yazar-Klosinski B, Emerson A. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology (Berl). 2018 Nov;235(11):3137-3148. doi: 10.1007/s00213-018-5010-9. Epub 2018 Sep 8. PubMed 30196397 ↗
  • Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS. MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:237-49. doi: 10.1016/j.pnpbp.2015.03.011. Epub 2015 Mar 25. PubMed 25818246 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share outcome data appearing in any published reports upon request.

Supporting information: Study protocol, Informed consent form

Time frame: Data and study-related documents will be available when all participants have completed the study

Access criteria: Interested persons should correspond with the central contact for the study.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Apr 2017, 36 months.

Results were first posted in Oct 2020, 3 years 5 months after primary completion. A results delay was requested in Sep 2018.

Of 44 phase 2 interventional studies under Autistic Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 62. This study's 36 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2013
First posted
Dec 11, 2013
StartActual
Apr 11, 2014
Primary completionActual
Apr 28, 2017
CompletionActual
Apr 28, 2017
Results delay requested
Sep 21, 2018
Results first posted
Oct 14, 2020
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02008396
Lead sponsor
Lykos Therapeutics
Collaborators
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Responsible party
Sponsor
First posted
Dec 11, 2013
Start date
Apr 11, 2014
Primary completion
Apr 28, 2017
Completion
Apr 28, 2017
Results posted
Oct 14, 2020
Last update
Jun 5, 2025

Study contacts

Charles S. Grob, MD
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion